It’s moving week at the Cost Curve offices, so the newsletter -- while it will appear -- is going to show up at slightly more random times. Thanks for your

My default assumption about most of the PBM reform proposals that have been circulating on Capitol Hill is that they’re smallball: they snack around the edge of the PBM business

Lots of earnings this morning that I haven’t processed yet. Hoping to give those a good look this weekend. Until then … The government formally responded to AstraZeneca’s lawsuit alleging

So I managed to screw up at least two things yesterday. First off, I misspelled Leana Wen’s name. Second, I included the wrong link in discussing Wen’s op-ed. The right

Yesterday was all about Eliquis. First up were the patient listening sessions I keep prattling on about. And while there was some sense that the parade of speakers didn’t shed

Below are transcripts (PDF) for all of the speakers at the CMS patient-focused listening sessions. Where possible, we've provided affiliations. CMS refers to speakers only with their first name, so

I’m on the road this week, which means I had the pleasure of overhearing a woman explaining the concept of a “beer back” to the patron sitting next to her

I don’t think there is a whole lot of analysis needed on the Commonwealth Fund’s look at the impact of high health care costs on consumers. A majority of the

Near-Term Programming Note: Cost Curve is off tomorrow, back Friday for AbbVie earnings and whatever other fun befalls us in the next 48 hours. Long-Term Programming Note: I plan to

  The Arc It’s a slow day today, so this is a brief Arc to prematurely flag an interesting trend: we’re a week or into pharma earnings season, and while